IL289338B1 - Therapeutic interactions of leucomethylthioninium - Google Patents
Therapeutic interactions of leucomethylthioniniumInfo
- Publication number
- IL289338B1 IL289338B1 IL289338A IL28933821A IL289338B1 IL 289338 B1 IL289338 B1 IL 289338B1 IL 289338 A IL289338 A IL 289338A IL 28933821 A IL28933821 A IL 28933821A IL 289338 B1 IL289338 B1 IL 289338B1
- Authority
- IL
- Israel
- Prior art keywords
- leucomethylthioninium
- therapeutic interactions
- interactions
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909493.7A GB201909493D0 (en) | 2019-07-01 | 2019-07-01 | Therapeutic interactions |
| PCT/EP2020/068422 WO2021001380A1 (en) | 2019-07-01 | 2020-06-30 | Therapeutic interactions of leucomethylthioninium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL289338A IL289338A (en) | 2022-02-01 |
| IL289338B1 true IL289338B1 (en) | 2026-03-01 |
Family
ID=67540109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289338A IL289338B1 (en) | 2019-07-01 | 2021-12-23 | Therapeutic interactions of leucomethylthioninium |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230031369A1 (https=) |
| EP (1) | EP3989954A1 (https=) |
| JP (1) | JP7638915B2 (https=) |
| KR (1) | KR20220027203A (https=) |
| CN (1) | CN114126622A (https=) |
| AU (1) | AU2020298758A1 (https=) |
| BR (1) | BR112021025256A2 (https=) |
| CA (1) | CA3143790A1 (https=) |
| GB (1) | GB201909493D0 (https=) |
| IL (1) | IL289338B1 (https=) |
| MX (1) | MX2021015292A (https=) |
| WO (1) | WO2021001380A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| JP7073330B2 (ja) * | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| FI4385512T3 (fi) * | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
-
2019
- 2019-07-01 GB GBGB1909493.7A patent/GB201909493D0/en not_active Ceased
-
2020
- 2020-06-30 MX MX2021015292A patent/MX2021015292A/es unknown
- 2020-06-30 CN CN202080048557.6A patent/CN114126622A/zh active Pending
- 2020-06-30 JP JP2021577641A patent/JP7638915B2/ja active Active
- 2020-06-30 KR KR1020227003213A patent/KR20220027203A/ko not_active Ceased
- 2020-06-30 WO PCT/EP2020/068422 patent/WO2021001380A1/en not_active Ceased
- 2020-06-30 US US17/620,949 patent/US20230031369A1/en not_active Abandoned
- 2020-06-30 EP EP20739286.1A patent/EP3989954A1/en active Pending
- 2020-06-30 CA CA3143790A patent/CA3143790A1/en active Pending
- 2020-06-30 BR BR112021025256A patent/BR112021025256A2/pt unknown
- 2020-06-30 AU AU2020298758A patent/AU2020298758A1/en active Pending
-
2021
- 2021-12-23 IL IL289338A patent/IL289338B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3989954A1 (en) | 2022-05-04 |
| MX2021015292A (es) | 2022-01-18 |
| KR20220027203A (ko) | 2022-03-07 |
| JP7638915B2 (ja) | 2025-03-04 |
| IL289338A (en) | 2022-02-01 |
| CN114126622A (zh) | 2022-03-01 |
| WO2021001380A1 (en) | 2021-01-07 |
| JP2022538642A (ja) | 2022-09-05 |
| GB201909493D0 (en) | 2019-08-14 |
| AU2020298758A1 (en) | 2022-02-24 |
| BR112021025256A2 (pt) | 2022-01-25 |
| US20230031369A1 (en) | 2023-02-02 |
| CA3143790A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202104461XA (en) | Therapeutic methods | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| HUE070489T2 (hu) | Lanifibranor deuterizált származékainak terápiás alkalmazása | |
| SG11202103253YA (en) | Therapeutic compounds | |
| ZA201906238B (en) | New therapeutical use of h3-ligands | |
| IL292502A (en) | Therapeutic methods using vadadustat | |
| GB2596732B (en) | Controlled disintegration of passage restriction | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| IL290983A (en) | Treatment methods | |
| ZA202106250B (en) | Therapeutic uses of dulaglutide | |
| IL289338B1 (en) | Therapeutic interactions of leucomethylthioninium | |
| GB201808150D0 (en) | Therapeutic compounds | |
| GB201916428D0 (en) | Treatment of hydro-carbon-contaminated materials | |
| GB201908885D0 (en) | Therapeutic compounds | |
| IL290039A (en) | Platelet assisted delivery of therapeutic compounds | |
| ZA202105399B (en) | Use of spiropidion | |
| GB201709136D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201918853D0 (en) | Methods of treatment | |
| GB201812861D0 (en) | Methods of administering therapy | |
| HK40073478A (en) | Therapeutic interactions of leucomethylthioninium | |
| ZA202003088B (en) | Treatment of tuberculosis | |
| GB201907647D0 (en) | Therapeutic methods | |
| GB201904341D0 (en) | Therapeutic methods | |
| GB201909438D0 (en) | Treatment of diseases |